Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis and ...
Sheikh SZ, Scheinberg MA, Wei JC,et al.Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.Lancet Rheumatol. 2021;3(2...
[摘要] 目的 分析贝利尤单抗治疗儿童狼疮性肾炎(LN)的有效性和安全性。方法 回顾性收集2021年7月1日至2024年7月31日在广西壮族自治区人民医院儿科接受贝利尤单抗治疗20周的12例LN患儿的临床资料。分析患儿治疗前后的临床表现、免疫和泌尿系统相关指标变化、疾病活动
Phase II trial of Belimumab did not meet its primary endpoint, which was a significant change in the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI). However, a significant decrease in SELENA-SLEDAI was seen in ANA positive patients.319Two...
Table 3. Population Pharmacokinetic Parameters in Adult Patients with SLE after Intravenous Infusion of BENLYSTA 10 mg/kga Lupus Nephritis A population pharmacokinetic analysis was conducted in 224 adult patients with lupus nephritis who received belimumab 10 mg/kg intravenously (Days 0, 14, 28, and...
Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program Background Belimumab is a recombinant, human, IgG1 monoclonal antibody that targets B-lymphocyte stimulator. The intravenous formulation is indicated for t... ...
SC phase III pivotal study of more than 800 patients with active SLE, which measured reduction in disease activity at Week 52 in patients receiving belimumab plus standard of care, versus those receiving placebo plus standard of care (assessed b...
Lymphocyte Stimulator and improves systemic lupus erythematosus (SLE) disease activity.ObjectivesThis study was initiated to evaluate the use and efficacy of belimumab in academic SLE clinical practices.MethodsAn invitation to participate was sent to 16 physicians experienced in SLE Phase III clinical ...
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchezguerrero J, Schwarting A, Merrill JT, Chatham WW (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythem...
(HealthDay)—The addition of belimumab versus placebo to standard therapy increases the likelihood of a primary efficacy renal response in patients with active lupus nephritis, according to a study published in the Sept. 17 issue of the New England Journ